843 related articles for article (PubMed ID: 19835971)
41. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
42. A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.
Khandelwal P; Fukuda T; Mizuno K; Teusink-Cross A; Mehta PA; Marsh RA; Kashuba ADM; Vinks AA; Davies SM
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1829-1835. PubMed ID: 27498124
[TBL] [Abstract][Full Text] [Related]
43. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
44. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients.
Bunchman T; Navarro M; Broyer M; Sherbotie J; Chavers B; Tönshoff B; Birk P; Lerner G; Lirenman D; Greenbaum L; Walker R; Zimmerhackl LB; Blowey D; Clark G; Ettenger R; Arterburn S; Klamerus K; Fong A; Tang H; Thomas S; Ramos E
Pediatr Nephrol; 2001 Dec; 16(12):978-84. PubMed ID: 11793083
[TBL] [Abstract][Full Text] [Related]
45. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation.
Mohty M; de Lavallade H; Faucher C; Bilger K; Vey N; Stoppa AM; Gravis G; Coso D; Viens P; Gastaut JA; Blaise D
Bone Marrow Transplant; 2004 Sep; 34(6):527-30. PubMed ID: 15286687
[TBL] [Abstract][Full Text] [Related]
46. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
[TBL] [Abstract][Full Text] [Related]
47. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation.
Skeens M; Pai V; Garee A; Termuhlen AM; Bajwa RP; Gross TG; Soni S
Bone Marrow Transplant; 2012 Nov; 47(11):1415-8. PubMed ID: 22484323
[TBL] [Abstract][Full Text] [Related]
48. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings.
Vogelsang GB; Arai S
Bone Marrow Transplant; 2001 Jun; 27(12):1255-62. PubMed ID: 11548843
[TBL] [Abstract][Full Text] [Related]
49. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation.
Okamura A; Yamamori M; Shimoyama M; Kawano Y; Kawano H; Kawamori Y; Nishikawa S; Minagawa K; Yakushijin K; Katayama Y; Sakaeda T; Hirai M; Matsui T
Int J Hematol; 2008 Jul; 88(1):104-110. PubMed ID: 18473127
[TBL] [Abstract][Full Text] [Related]
51. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation.
David-Neto E; Pereira Araujo LM; Sumita NM; Mendes ME; Ribeiro Castro MC; Alves CF; Kakehashi E; Romano P; Yagyu EM; Queiroga M; Nahas WC; Ianhez LE
Pediatr Nephrol; 2003 Mar; 18(3):266-72. PubMed ID: 12644921
[TBL] [Abstract][Full Text] [Related]
52. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis.
Perkins J; Field T; Kim J; Kharfan-Dabaja MA; Fernandez H; Ayala E; Perez L; Xu M; Alsina M; Ochoa L; Sullivan D; Janssen W; Anasetti C
Biol Blood Marrow Transplant; 2010 Jul; 16(7):937-47. PubMed ID: 20102746
[TBL] [Abstract][Full Text] [Related]
53. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation.
Jacobson P; Rogosheske J; Barker JN; Green K; Ng J; Weisdorf D; Tan Y; Long J; Remmel R; Sawchuk R; McGlave P
Clin Pharmacol Ther; 2005 Nov; 78(5):486-500. PubMed ID: 16321615
[TBL] [Abstract][Full Text] [Related]
54. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
56. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Choi SW; Braun T; Chang L; Ferrara JL; Pawarode A; Magenau JM; Hou G; Beumer JH; Levine JE; Goldstein S; Couriel DR; Stockerl-Goldstein K; Krijanovski OI; Kitko C; Yanik GA; Lehmann MH; Tawara I; Sun Y; Paczesny S; Mapara MY; Dinarello CA; DiPersio JF; Reddy P
Lancet Oncol; 2014 Jan; 15(1):87-95. PubMed ID: 24295572
[TBL] [Abstract][Full Text] [Related]
57. Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects.
Almeida S; Filipe A; Neves R; Spínola AC; Tanguay M; Ortuño J; Farré A; Torns A
Clin Ther; 2010 Mar; 32(3):556-74. PubMed ID: 20399993
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
[TBL] [Abstract][Full Text] [Related]
59. Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT.
Weber T; Niestadtkötter J; Wienke A; Müller-Tidow C; Müller LP
Eur J Haematol; 2016 Sep; 97(3):232-8. PubMed ID: 26613546
[TBL] [Abstract][Full Text] [Related]
60. Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation.
Kolb M; Offer K; Jin Z; Kahn J; Bhatia M; Kung AL; Garvin JH; George D; Satwani P
Biol Blood Marrow Transplant; 2016 May; 22(5):957-61. PubMed ID: 26880117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
